Velicept Therapeutics, Inc. is a privately held, clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs. Its lead program, solabegron, is a highly differentiated novel compound being investigated for overactive bladder (OAB) and irritable bowel syndrome (IBS).
Solabegron has completed and demonstrated positive results in initial Phase II clinical studies for the treatment of overactive bladder (OAB) in women and irritable bowel syndrome (IBS).
NEWS + EVENTS
Malvern, PA, December 1, 2015 (BUSINESS WIRE) – Velicept Therapeutics, Inc. announced today it has closed on the first tranche of a $21 million Series B financing…